(Date:11/5/2009)... , GAITHERSBURG, Md., Nov. 5 /PRNewswire-Firs...unced its financial results for the third quarter ...ss of $3.6 million ($0.04 per share) for the three... loss of $6.8 million ($0.08 per share) in the com... September 30, 2009, GenVec,s net loss was $14.1 m...
(Date:11/5/2009)... , PARSIPPANY, N.J., Nov. 5 D... has made a manufacturing alliance with Galenix, S...referred commercial scale manufacturing partner fo..., DSM and Galenix will collaborate on business ...g delivery technologies, based on the strength of ...
(Date:11/5/2009)... , RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire...), a leading supplier of innovative products for p...rted results for the first quarter of fiscal 2010....he Company reported revenues of $5.2 million, a 15... the first quarter a year ago. The Company said th...
(Date:11/5/2009)... , OMAHA, Neb., Nov. 5 /PRNewswire-FirstCall/...today announced financial results for the quarter ...results are presented in the tables that follow. ,...ed a net loss of $366,000 or $0.01 per share for t... of $499,000 or $0.01 per share for the third quar...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7... , Introduction , CypHer5 TM...is non-fluorescent at pH 7.4 and maximally fluores... monitoring internalization of cell surface recept...mulation (1, 2). , <P ,>In the assay, ... recognizing the tag is then labelled with CypHer5...
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ...liver outstanding electrophoretic transfer results...nt of buffer. , • Units availabl... maximum flexibility , • Complet...rylamide gels in less than 1 h , • ...
... , , Key words: adenoviral vec... IN Cell Analyzer ● gene delivery, ...nd primary cells can greatly aid secondary screeni...r development presents several challenges. Establi...of interest at detectable levels takes time. In ad...
Other Biology Technology:The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 2The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 3The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 4The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 5The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 6ECL Semi-dry Blotters 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8Rabbit Anti-Human SNAPAP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Goat Anti-Mouse Complement Component C5a Polyclonal Antibody, Unconjugated from R&D Systems
Goat Anti-Human CXCL14 / BRAK Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human RXRA Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: